ReviewThe Journal of antibiotics2019
Lactacystin: first-in-class proteasome inhibitor still excelling and an exemplar for future antibiotic research.
Review in The Journal of antibiotics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Five-layer systems analysis ofeLife · 2026Article
- Article
- Targeting the proteasome in cancer therapy: development and future opportunities in natural products.Frontiers in pharmacology · 2026Review
- Ubiquitination dynamics in human tumour viruses: Viral infection, oncogenesis and antiviral therapy.The FEBS journal · 2026Review
- Epigenetic mechanisms of HIV and opioid-induced neuropathology: Potential therapies and interventions.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Ethyl 4-[(2-hy-droxy-eth-yl)amino]-2-(4-meth-oxyphen-yl)-1-methyl-5-oxo-2,5-di-hydro-1IUCrData · 2024Article
- Human metapneumovirus SH protein promotes JAK1 degradation to impair host IL-6 signaling.Journal of virology · 2024Article
- PRMT5/WDR77 Enhances the Proliferation of Squamous Cell Carcinoma via the ΔNp63α-p21 Axis.Cancers · 2024Article
- Lifelong dietary protein restriction induces denervation and skeletal muscle atrophy in mice.Free radical biology & medicine · 2024Article
- Human metapneumovirus SH protein promotes JAK1 degradation to impair host IL-6 signaling.bioRxiv : the preprint server for biology · 2024Article
- Cobalt-Catalyzed Aerobic Aminocyclization of Unsaturated Amides for the Synthesis of Functionalized γ- and δ-Lactams.Organic letters · 2023Article
- Regulation of TRIB1 abundance in hepatocyte models in response to proteasome inhibition.Scientific reports · 2023Article
- Article
- The roles of ubiquitin-proteasome system and regulator of G protein signaling 4 in behavioral sensitization induced by a single morphine exposure.Brain and behavior · 2023Article
- A53T mutant α-synuclein fibrils formed in macrophage are spread to neurons.Cellular and molecular life sciences : CMLS · 2022Article
- Ivermectin represses Wnt/β-catenin signaling by binding to TELO2, a regulator of phosphatidylinositol 3-kinase-related kinases.iScience · 2022Article
- Lactacystin-induced kidney fibrosis: Protection by melatonin and captopril.Frontiers in pharmacology · 2022Article
- Peroxiredoxin 6 Modulates Insulin Secretion and Beta Cell DeathFrontiers in endocrinology · 2022Article
- Proteolysis and multimerization regulate signaling along the two-component regulatory system AdeRS.iScience · 2021Article
- Ubiquitin-related processes and innate immunity in C. elegans.Cellular and molecular life sciences : CMLS · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactacystin exemplifies the role that serendipity plays in drug discovery and why "finding things without actually looking for them" retains such a pivotal role in the search for the useful properties of chemicals. The first proteasome inhibitor discovered, lactacystin stimulated new possibilities in cancer control. New and innovative uses are regularly being found for lactacystin, including as a model to study dementia, while new formulations and delivery systems may facilitate its use clinically as an anticancer agent. All this provides yet more evidence that we need a comprehensive, collaborative and coordinated programme to fully investigate all new and existing chemical compounds, especially those of microbial origin. We need to do so in order to avoid failing to detect and successfully exploit unsought yet potentially life-saving or extremely advantageous properties of microbial metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.